研究成果

[雑誌論文] C16, a PKR inhibitor, suppresses cell proliferation by regulating the cell cycle via p21 in colorectal cancer

Hashimoto Yu、Tokumoto Yoshio、Hiasa Yoichi、et al. 2024

[図書] 今日の治療指針　202年版: 私はこう治療している

日浅陽一　(編)福井次矢、高木　誠、小室一成 2024

[雑誌論文] Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria

Ohama Hideko、Hiraoka Atsushi、Hiasa Yoichi、et al. 2023

[図書] 解剖生理からみちびく消化器ケア Q＆A108: イラスト×写真で機能・検査・疾患・治療・ケアのギモンが解決！

廣岡昌史、日浅陽一　(編)李　相雄 2023

[学会発表] Atezolizumab plus bevacizumab therapy for hepatocellular carcinoma: The Geriatric Nutritional Risk Index as a convenient prognostic evaluation tool.

Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al. 2023

[雑誌論文] Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al. 2023

[学会発表] C型肝硬変におけるSVR後の肝予備能と肝発癌の予測

渡辺崇夫、徳本良雄一、日浅陽一 2023

[学会発表] 初回治療として根治術を施行した肝細胞癌患者におけるSVR時期と予後の検討

多田藤政、中谷康輔、日浅陽一　他 2023

[図書] 消化器内科診療Controversy

廣岡昌史、日浅陽一　(編)竹原徹郎 2023

[学会発表] 門脈圧亢進症を伴った切除不能肝細胞癌患者におけるAtezolizumab+Bevacizumabの治療成績

多田藤政、多田俊史、日浅陽一　他 2023

[雑誌論文] Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation

Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al. 2023

[雑誌論文] Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function

Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al. 2023

[学会発表] Clinical usefulness of lenvatinib as second-line treatment for hepatocellular carcinoma following atezolizumab plus bevacizumab failure.

Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al. 2023

[雑誌論文] Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals

Watanabe Takao、Tokumoto Yoshio、Hiasa Yoichi、et al. 2023

[雑誌論文] Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria ? Multicenter analysis

Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Kakizaki S、Shimada N、Kawata K、Naganuma A、Tanaka T、Ohama H、Nouso K、Morishita A、Hiasa Y、Kudo M、et al. 2022

[雑誌論文] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Ohama H、Nouso K、Morishita A、Tsutsui A、Nagano T、Itokawa N、Hiasa Y、Kudo M、et al. 2022

[雑誌論文] Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study

Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma

Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al. 2022

[雑誌論文] Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Does first‐line treatment have prognostic impact for unresectable HCC? -Atezolizumab plus bevacizumab versus lenvatinib

Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al. 2022

[雑誌論文] The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis

Hatanaka Takeshi、Naganuma Atsushi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Tanaka Takaaki、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al. 2022

[雑誌論文] A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study

Liu Chuan、Cao Zhujun、Yan Huadong、Hiasa Yoichi、et al. 2022

[雑誌論文] New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al. 2022

[雑誌論文] Development and validation of a modified albumin?bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis

Hatanaka Takeshi、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al. 2022

[雑誌論文] Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment

Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al. 2022

[雑誌論文] Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis

Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al. 2022

[雑誌論文] Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

Hiraoka A、Kumada T、Tada T、Tani J、Kariyama K、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Aoki T、Tanaka T、Ohama H、Hiasa Y、Kudo M、et al. 2021

[雑誌論文] Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Rimini M、Shimose S、Lonardi S、Tada T、Masi G、Iwamoto H、Lai E、Burgio V、Hiraoka A、Ishikawa T、Solda C、Shirono T、Vivaldi C、Takaguchi K、Shimada N、Astara G、Koga H、Nouso K、Joko K、Torimura T、Hiasa Y、Salani F、Scartozzi M、Cascinu S、Casadei GA. 2021

[雑誌論文] Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

Rapposelli IG、Tada T、Shimose S、Burgio V、Kumada T、Iwamoto H、Hiraoka A、Niizeki T、Atsukawa M、Koga H、Hirooka M、Torimura T、Iavarone M、Tortora R、Campani C、Lonardi S、Tamburini E、Piscaglia F、Masi G、Cabibbo G、Giuseppe FF、Silletta M、Tsuji K、Ishikawa T、Hiasa Y、Casadei GA、et al. 2021

[雑誌論文] Radiofrequency Ablation Covering the Entire Tumor Blood Drainage Area Improves Survival in Hepatocellular Carcinoma

Hirooka M、Koizumi Y、Tanaka T、Sunago K、Nakamura Y、Watanabe T、Yoshida O、Tokumoto Y、Abe M、Hiasa Y. 2021

[雑誌論文] Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis

Tada T、Kumada T、Hiraoka A、Michitaka K、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Nakamura S、Nouso K、Tsutsui A、Nagano T、Hiasa Y、et al. 2021

[雑誌論文] Impact of modified albumin?bilirubin grade on survival in patients with HCC who received lenvatinib

Tada T、Kumada T、Hiraoka A、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Tani J、Nakamura S、Nouso K、Tsutsui A、Nagano T、Takaaki T、Hiasa Y、et al. 2021

[雑誌論文] Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression

Hiraoka A、Kumada T、Hatanaka T、Tada T、Kariyama K、Tani J、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Ogawa C、Tamai T、Kakizaki S、Tojima H、Hiasa Y、Kudo M、et al. 2021